Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast): A Phase 2 Study on Fulvestrant Beyond Progression in Combination With Alpelisib for PIK3CA-mutated, Hormone-receptor Positive HER2 Negative Advanced Breast Cancer

NCT05392608 is registered in ClinicalTrials.gov with Borstkanker Onderzoek Groep as lead sponsor.

NCT NCT05392608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05392608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast): A Phase 2 Study on Fulvestrant Beyond Progression in Combination With Alpelisib for PIK3CA-mutated, Hormone-receptor Positive HER2 Negative Advanced Breast Cancer
Lead sponsor
Borstkanker Onderzoek Groep
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 2, 2022
Completion date
March 31, 2028
Enrollment
130 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

congenital, familial and genetic disorders, neoplasm, breast